Neurofibrosarcoma Market Summary
- The Neurofibrosarcoma Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
- The Neurofibrosarcoma companies developing therapies in the treatment landscape include - Highlight Therapeutics, Adaptimmune , Bristol-Myers Squibb, Taiho Pharmaceuticals, Inc, Epizyme, Inc, Ascentage Pharma Group Inc, Merck Sharp & Dohme LLC, Tango Therapeutics, Inc, HRYZ Biotech Co, Stella Pharma Corporation, and others.
Neurofibrosarcoma Market and Epidemiology Analysis
- Currently, there are no approved therapies for neurofibrosarcoma. Surgery remains the mainstay of treatment, while radiation therapy helps lower recurrence risk, particularly in high-grade or incompletely resected cases. Chemotherapy provides limited benefit in metastatic, unresectable, or high risk patients. Optimal care requires a multidisciplinary approach.
- The emerging treatment landscape for neurofibrosarcoma includes several promising therapies, such as TECELRA (afamitresgene autoleucel), BO-112, sotigalimab (PYX-107), and others.
- Several companies are actively developing therapies for neurofibrosarcoma, including Adaptimmune, Highlight Therapeutics, Pyxis Oncology, and others.
- In a nutshell, no therapies are approved for neurofibrosarcoma, but promising candidates like afamitresgene autoleucel, BO-112, and sotigalimab may reshape the market during the forecast period (2025–2034).
- In December 2024, Pyxis Oncology shifted its focus to developing its main drug, micvotabart pelidotin, and put PYX-107 development on hold. Due to uncertainty about its future and a decline in value, the company wrote off PYX-107, resulting in a USD 21 million non cash loss for 2024. Despite this, the company remains optimistic about PYX-107’s potential and may reconsider its development based on new data from ongoing research.
Request for unlocking the Sample Page of the "Neurofibrosarcoma Market Insights"
Key Factors Driving the Neurofibrosarcoma Market
- Rising Awareness and Improved Diagnosis: Increased clinical awareness and advances in imaging and molecular diagnostics are enabling earlier and more accurate identification of neurofibrosarcoma cases.
- High Unmet Medical Need: Limited effective treatment options for advanced and recurrent disease are driving demand for novel targeted therapies and innovative treatment approaches.
- Advancements in Targeted and Immunotherapies: Progress in molecular biology and immuno-oncology is supporting the development of targeted agents and cell-based therapies, improving treatment potential.
- Growing Research and Clinical Trial Activity: Expanding clinical pipelines and increased investment in rare cancer research are accelerating drug development and therapeutic innovation.
- Supportive Regulatory Frameworks for Rare Cancers: Orphan drug incentives, fast-track designations, and expedited approval pathways are encouraging pharmaceutical companies to invest in neurofibrosarcoma treatments.
DelveInsight's "Neurofibrosarcoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Neurofibrosarcoma, historical and forecasted epidemiology as well as the Neurofibrosarcoma therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Neurofibrosarcoma market report provides current treatment practices, emerging drugs, Neurofibrosarcoma market share of the individual therapies, current and forecasted Neurofibrosarcoma market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Neurofibrosarcoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Neurofibrosarcoma market.
Scope of the Neurofibrosarcoma Market | |
|
Study Period |
2020 to 2034 |
|
Forecast Period |
2024-2034 |
|
Geographies Covered |
|
|
Neurofibrosarcoma Market |
|
|
Neurofibrosarcoma Market Size | |
|
Neurofibrosarcoma Companies |
Highlight Therapeutics, Adaptimmune , Bristol-Myers Squibb, Taiho Pharmaceuticals, Inc, Epizyme, Inc, Ascentage Pharma Group Inc, Merck Sharp & Dohme LLC, Tango Therapeutics, Inc, HRYZ Biotech Co, Stella Pharma Corporation, and others |
|
Neurofibrosarcoma Epidemiology Segmentation |
|
Neurofibrosarcoma Disease Understanding
The DelveInsight’s Neurofibrosarcoma market report gives a thorough understanding of the Neurofibrosarcoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Neurofibrosarcoma Overview
Neurofibrosarcoma, also known as malignant peripheral nerve sheath tumor (MPNST), is a rare and aggressive soft tissue sarcoma arising from peripheral nerve sheaths or pre-existing neurofibromas. It is most commonly associated with neurofibromatosis type 1 (NF1) but can also occur sporadically. The disease typically presents as a rapidly enlarging, painful mass and has a high risk of local recurrence and distant metastasis, particularly to the lungs. Due to its rarity and biological complexity, neurofibrosarcoma poses significant diagnostic and therapeutic challenges, underscoring the need for early detection and specialized, multidisciplinary care.
Neurofibrosarcoma Diagnosis
Neurofibrosarcoma is typically diagnosed through a combination of clinical evaluation, imaging, and histopathological analysis. Patients often present with a rapidly enlarging, painful soft-tissue mass, frequently arising from peripheral nerves or pre-existing neurofibromas. Imaging techniques such as Magnetic Resonance Imaging (MRI) Devices are the preferred modality to assess tumor size, extent, and involvement of surrounding structures, while CT scans may be used to detect metastasis. Definitive diagnosis requires a tissue biopsy, with histology showing malignant spindle cells. Immunohistochemical markers, including S-100 (often reduced or focal), help differentiate neurofibrosarcoma from other soft tissue sarcomas. Molecular testing may support diagnosis in selected cases.
Neurofibrosarcoma Treatment
The primary treatment for neurofibrosarcoma is complete surgical resection with clear margins, as surgery offers the best chance for local disease control. Adjuvant radiation therapy is often recommended, especially for high-grade tumors or cases with positive or close surgical margins, to reduce the risk of local recurrence. Chemotherapy has a limited role and is generally considered for advanced, metastatic, or unresectable disease, with modest clinical benefit. Due to the aggressive nature of neurofibrosarcoma, treatment planning typically involves a multidisciplinary team, including surgical oncologists, radiation oncologists, and medical oncologists.
It covers the details of conventional and current medical therapies available in the Neurofibrosarcoma market for the treatment of the condition. It also provides Neurofibrosarcoma treatment algorithms and guidelines in the United States, Europe, and Japan.
Neurofibrosarcoma Epidemiology
The Neurofibrosarcoma epidemiology section provides insights about the historical and current Neurofibrosarcoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Neurofibrosarcoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings from Neurofibrosarcoma Epidemiological Analyses and Forecast
The Neurofibrosarcoma epidemiology covered in the report provides historical as well as forecasted Neurofibrosarcoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
- The emerging treatment landscape for neurofibrosarcoma includes several promising therapies, such as TECELRA (afamitresgene autoleucel), BO-112, sotigalimab (PYX-107), and others.
- Several companies are actively developing therapies for neurofibrosarcoma, including Adaptimmune, Highlight Therapeutics, Pyxis Oncology, and others.
- Currently, there are no approved therapies for neurofibrosarcoma. Surgery remains the mainstay of treatment, while radiation therapy helps lower recurrence risk, particularly in high-grade or incompletely resected cases. Chemotherapy provides limited benefit in metastatic, unresectable, or high risk patients. Optimal care requires a multidisciplinary approach.
- According to Orphanet, Incidence of MPNST in the general population has been reported to be 1/100,000. MPNSTs account for about 5 to 10% of all soft tissue sarcomas. The sex ratio is about equal. Incidence NF1 is reported to be approximately 5 to 10%.
- In a nutshell, no therapies are approved for neurofibrosarcoma, but promising candidates like afamitresgene autoleucel, BO-112, and sotigalimab may reshape the market during the forecast period (2025–2034).
Country Wise- Neurofibrosarcoma Epidemiology
The epidemiology segment also provides the Neurofibrosarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Neurofibrosarcoma Epidemiology Segmentation
- Total Incidence Cases of Neurofibrosarcoma in the 7MM
- Age-specific Cases of Neurofibrosarcoma in the 7MM
- Gender-specific Cases of Neurofibrosarcoma in the 7MM
- NF1- Associated Cases of Neurofibrosarcoma in the 7MM
- Total Treated Cases of Neurofibrosarcoma in the 7MM
Neurofibrosarcoma Drug Analysis
The drug chapter segment of the Neurofibrosarcoma report encloses the detailed analysis of Neurofibrosarcoma marketed drugs and late-stage (Phase-III and Phase-II) Neurofibrosarcoma pipeline drugs. It also helps to understand the Neurofibrosarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Neurofibrosarcoma Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Neurofibrosarcoma treatment.
Neurofibrosarcoma Emerging Drugs
The key pharmaceutical players are Adaptimmune, Highlight Therapeutics, Pyxis Oncology, and others. The launch of afamitresgene autoleucel, BO-112, and others is expected to bring forth new treatment options to neurofibrosarcoma patients, significantly boosting the growth in the neurofibrosarcoma market size.
TECELRA (afamitresgene autoleucel): Adaptimmune
Afamitresgene autoleucel (afami-cel), developed by Adaptimmune, is an investigational T-cell receptor (TCR) therapy designed to target tumors expressing MAGE-A4, a cancer-testis antigen.
- A key development for malignant peripheral nerve sheath tumors (MPNST) is the ongoing Phase II SPEARHEAD-3 trial (NCT05642455), a pediatric basket study evaluating afami-cel in HLA-A\*02-positive patients aged 2–21 with MAGE-A4-positive cancers, including MPNST, neuroblastoma, and osteosarcoma. The trial primarily focuses on assessing safety, efficacy, and the durability of responses in heavily pretreated patients.
- As of 2025, the trial remains actively recruiting. Preclinical and translational data further support the potential of afami-cel in treating other MAGE-A4 positive tumors such as MPNST.
BO-112: Highlight Therapeutics
The combination of BO-112, nivolumab, and radiation therapy is being explored as a potential treatment strategy for malignant peripheral nerve sheath tumors (MPNST). This approach is currently being evaluated in a Phase I clinical trial (NCT04420975) for patients with resectable soft tissue sarcomas, including MPNST, synovial sarcoma, and leiomyosarcoma. BO-112 is an immunotherapy agent designed as a nanoplexed form of polyinosinic:polycytidylic acid (poly I:C), a synthetic double-stranded RNA (dsRNA) that mimics viral genetic material. Its mechanism of action involves several key immunostimulatory pathways.
- Preclinical studies have demonstrated that combining BO-112 with radiation therapy can enhance CD8 T-cell mediated tumor control. The addition of nivolumab may further potentiate this effect by preventing the suppression of T-cell activity within the tumor microenvironment.
Neurofibrosarcoma Market Outlook
The Neurofibrosarcoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Neurofibrosarcoma market trends by analyzing the impact of current Neurofibrosarcoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Neurofibrosarcoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neurofibrosarcoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Neurofibrosarcoma market in 7MM is expected to witness a major change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Neurofibrosarcoma market in 7MM.
The United States Neurofibrosarcoma Market Outlook
This section provides the total Neurofibrosarcoma market size and market size by therapies in the United States.
EU-5 Countries Neurofibrosarcoma Market Outlook
The total Neurofibrosarcoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Neurofibrosarcoma Market Outlook
The total Neurofibrosarcoma market size and market size by therapies in Japan is also mentioned.
Neurofibrosarcoma Competitive Landscape
Key Neurofibrosarcoma Companies
The Key Neurofibrosarcoma companies actively involved in the Neurofibrosarcoma treatment landscape include -
- Highlight Therapeutics
- Adaptimmune
- Bristol-Myers Squibb
- Taiho Pharmaceuticals, Inc
- Epizyme, Inc
- Ascentage Pharma Group Inc
- Merck Sharp & Dohme LLC
- Tango Therapeutics, Inc
- HRYZ Biotech Co
- Stella Pharma Corporation, and others
Neurofibrosarcoma Drugs Uptake
This section focuses on the rate of uptake of the potential Neurofibrosarcoma drugs recently launched in the Neurofibrosarcoma market or expected to get launched in the market during the study period 2020-2034. The analysis covers Neurofibrosarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Neurofibrosarcoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Neurofibrosarcoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Neurofibrosarcoma Clinical Trial Activities
The Neurofibrosarcoma pipeline report provides insights into Neurofibrosarcoma clinical trials within Phase II, and Phase III stage. It also analyses Neurofibrosarcoma key players involved in developing targeted therapeutics.
Neurofibrosarcoma Pipeline Development Activities
The Neurofibrosarcoma clinical trial analysis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Neurofibrosarcoma emerging therapies.
Neurofibrosarcoma Market Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Latest KOL- Views on Neurofibrosarcoma Market Report
To keep up with current Neurofibrosarcoma market trends, we take KOLs and SMEs ' opinion working in the Neurofibrosarcoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Neurofibrosarcoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Neurofibrosarcoma Market Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Neurofibrosarcoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Neurofibrosarcoma Market Report
- The report covers the descriptive overview of Neurofibrosarcoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Neurofibrosarcoma epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Neurofibrosarcoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Neurofibrosarcoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neurofibrosarcoma market
Neurofibrosarcoma Market Report Highlights
- In the coming years, the Neurofibrosarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Neurofibrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Neurofibrosarcoma. The launch of emerging therapies will significantly impact the Neurofibrosarcoma market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neurofibrosarcoma
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Neurofibrosarcoma Market Report Insights
- Neurofibrosarcoma Patient Population
- Neurofibrosarcoma Therapeutic Approaches
- Neurofibrosarcoma Pipeline Analysis
- Neurofibrosarcoma Market Size and Trends
- Neurofibrosarcoma Market Opportunities
- Impact of upcoming Neurofibrosarcoma Therapies
Neurofibrosarcoma Market Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Neurofibrosarcoma Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Neurofibrosarcoma Drugs Uptake
Neurofibrosarcoma Market Report Assessment
- Current Neurofibrosarcoma Treatment Practices
- Neurofibrosarcoma Unmet Needs
- Neurofibrosarcoma Pipeline Product Profiles
- Neurofibrosarcoma Market Attractiveness
- Neurofibrosarcoma Market Drivers
- Neurofibrosarcoma Market Barriers
Key Questions Answered In The Neurofibrosarcoma Market Report:
Neurofibrosarcoma Market Insights:
- What was the Neurofibrosarcoma drug class share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Neurofibrosarcoma total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Neurofibrosarcoma market size during the forecast period (2020-2034)?
- At what CAGR, the Neurofibrosarcoma market is expected to grow by 7MM during the forecast period (2020-2034)?
- What would be the Neurofibrosarcoma market outlook across the 7MM during the forecast period (2020-2034)?
- What would be the Neurofibrosarcoma market growth till 2034, and what will be the resultant market Size in the year 2034?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Neurofibrosarcoma Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Neurofibrosarcoma?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Neurofibrosarcoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Neurofibrosarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neurofibrosarcoma?
- Out of all 7MM countries, which country would have the highest prevalent population of Neurofibrosarcoma during the forecast period (2020-2034)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Neurofibrosarcoma Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Neurofibrosarcoma treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Neurofibrosarcoma in the USA, Europe, and Japan?
- What are the Neurofibrosarcoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Neurofibrosarcoma?
- How many therapies are in-development by each company for Neurofibrosarcoma treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Neurofibrosarcoma treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Neurofibrosarcoma therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neurofibrosarcoma and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Neurofibrosarcoma?
- What are the global historical and forecasted market of Neurofibrosarcoma?
Reasons to buy Neurofibrosarcoma Market Forecast Report
- The report will help in developing business strategies by understanding trends shaping and driving the Neurofibrosarcoma market
- To understand the future market competition in the Neurofibrosarcoma market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Neurofibrosarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Neurofibrosarcoma market
- To understand the future market competition in the Neurofibrosarcoma market
